Publication | Closed Access
A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
91
Citations
20
References
2002
Year
LA-2550 (22.5 mg. depot) produced and maintained safe and effective suppression of serum testosterone to well below the medical castrate level of 50 ng./dl. or less.
| Year | Citations | |
|---|---|---|
Page 1
Page 1